UK shares have experienced a notable downturn in recent weeks, primarily driven by escalating geopolitical tensions that have unsettled global markets. The FTSE 100, the UK’s benchmark stock index, has undergone a correction, defined as a decline of at least 10% over a relatively short period. These fluctuations in stock markets are not uncommon, yet they can be disconcerting for investors.
In the face of market dips, some investors might feel compelled to sell their shares to minimize losses, while others may see an opportunity to acquire undervalued stocks. The question now arises: what is the most prudent strategy amid this uncertainty?
According to insights from The Motley Fool, the inevitable short-term volatility in the market is a trade-off for achieving the superior long-term returns associated with equities. The trajectory of stock prices is rarely linear; they fluctuate, occasionally experiencing steep declines. For investors who have a short-term financial horizon, it is advised not to place their money in stocks. However, for those investing for the long haul, such as retirement savings, equities can offer significant growth potential.
Market downturns can provide strategic opportunities for investors willing to take calculated risks. Purchasing shares that have fallen in value can yield lower valuations and higher dividend yields. Yet, such decisions require a strong conviction, especially in today’s climate. Historical patterns, such as buying during the 2020 COVID-19 crash or the market’s reaction to geopolitical events like Russia’s invasion of Ukraine, showed that those who remained steadfast often reaped rewards. However, this time, there are valid concerns that investors must consider.
Currently, a significant number of FTSE 100 stocks have experienced declines of 20% or more in a matter of weeks. Rather than committing large sums all at once, a more pragmatic approach could be to gradually invest in equities, allowing investors to capitalize on lower price points over time.
Stock selection is crucial during these turbulent times. One notable performer within the FTSE 100 is pharmaceutical giant GSK (LSE: GSK). The company has been in a lengthy rebuilding phase, prioritizing the reinvestment of savings from frozen dividends to enhance its drug and vaccine pipeline, thereby bolstering future revenue streams. Although the GSK share price has seen a dip of about 7% in the last month, this aligns with the broader trends of the FTSE 100. Nevertheless, GSK’s stock has appreciated nearly 40% over the past year, presenting a potentially advantageous entry point for investors now.
The current price-to-earnings ratio of approximately 11.9 reflects that GSK may still offer decent value, despite its share price currently being depressed. This valuation has remained low for some time, suggesting an investor reluctance to drive the shares higher. With a dividend yield hovering around 3.2%, income-focused investors may need to adjust their expectations or explore alternative higher-yielding opportunities available in the market.
Despite inherent risks—including the costly and uncertain nature of drug development, concerns over U.S. tariffs, and intense industry competition—GSK appears to be a solid addition for long-term investors. While it may not be the flashiest stock within the UK market, it can play a valuable role in a diversified portfolio, complementing investments in higher-growth or higher-yielding sectors.
